StockDuty ← Dashboard Nov 08, 2026 10:53 AM ET
SignalCorporate

$ASND got an EMA orphan maintenance opinion for TransCon CNP in pediatric achondroplasia, keeping 10-year EU exclusivity in play. CHMP already backed approval for kids 2+ whose epiphyses are not close

$ASND got an EMA orphan maintenance opinion for TransCon CNP in pediatric achondroplasia, keeping 10-year EU exclusivity in play. CHMP already backed approval for kids 2+ whose epiphyses are not close

ASND
$252.61
-1.31%
$ASND got an EMA orphan maintenance opinion for TransCon CNP in pediatric achondroplasia, keeping 10-year EU exclusivity in play. CHMP already backed approval for kids 2+ whose epiphyses are not close
$ASND got an EMA orphan maintenance opinion for TransCon CNP in pediatric achondroplasia, keeping 10-year EU exclusivity in play. CHMP already backed approval for kids 2+ whose epiphyses are not close — impact context not separately stored; see What changed.
Sources